Psychedelics Promote Structural and Functional Neural Plasticity
Calvin Ly,Alexandra C. Greb,Lindsay P. Cameron,Jonathan M. Wong,Eden V. Barragan,Paige C. Wilson,Kyle F. Burbach,Sina Soltanzadeh Zarandi,Alexander Sood,Michael R. Paddy,Whitney C. Duim,Megan Y. Dennis,A. Kimberley McAllister,Kassandra M. Ori-McKenney,John A. Gray,David E. Olson +15 more
Reads0
Chats0
TLDR
It is reported that, like ketamine, serotonergic psychedelics are capable of robustly increasing neuritogenesis and/or spinogenesis both in vitro and in vivo.About:
This article is published in Cell Reports.The article was published on 2018-06-12 and is currently open access. It has received 436 citations till now.read more
Citations
More filters
Journal ArticleDOI
Will psilocybin lose its magic in the clinical setting?
TL;DR: The difficulties that may arise as psilocybin emerges from the research setting, which may hamper its progress towards becoming a licenced medication, are considered.
Journal ArticleDOI
Tolerance and Cross-Tolerance among Psychedelic and Nonpsychedelic 5-HT2A Receptor Agonists in Mice.
Mario de la Fuente Revenga,Alaina M Jaster,John McGinn,Gabriella Silva,Somdatta Saha,Javier González-Maeso +5 more
TL;DR: Tolerance to HTR induced by psychedelics involves activation of the 5-HT2AR, is not observable upon repeated administration of nonpsychedelic 5- HT2AR agonists, and occurs via a signaling mechanism independent of β-arrestin-2.
Journal ArticleDOI
Psychedelics in the treatment of unipolar and bipolar depression
TL;DR: The role of classic and two atypical psychedelics in the treatment of unipolar and bipolar depression was discussed in this article , where a narrative review of the role of LSD and ketamine was presented.
Journal ArticleDOI
Where do we go next in antidepressant drug discovery? A new generation of antidepressants: a pivotal role of AMPA receptor potentiation and mGlu2/3 receptor antagonism
TL;DR: The mechanism of action of these compounds suggests a strong glutamatergic component that involves the facilitation of AMPA receptor function, which appears to be relevant to the antidepressant pharmacology of this new class of drugs.
References
More filters
Journal ArticleDOI
Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010.
Harvey Whiteford,Harvey Whiteford,Louisa Degenhardt,Louisa Degenhardt,Juergen Rehm,Juergen Rehm,Amanda J Baxter,Amanda J Baxter,Alize J. Ferrari,Alize J. Ferrari,Holly E. Erskine,Holly E. Erskine,Fiona J Charlson,Fiona J Charlson,Rosana E. Norman,Rosana E. Norman,Abraham D. Flaxman,Nicole E. Johns,Roy Burstein,Christopher J L Murray,Theo Vos +20 more
TL;DR: The Global Burden of Diseases, Injuries, and Risk Factors Study 2010 (GBD 2010) as discussed by the authors was used to estimate the burden of disease attributable to mental and substance use disorders in terms of disability-adjusted life years (DALYs), years of life lost to premature mortality (YLLs), and years lived with disability (YLDs).
Journal ArticleDOI
Acute and Longer- Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report
A. John Rush,Madhukar H. Trivedi,Stephen R. Wisniewski,Andrew A. Nierenberg,Jonathan W. Stewart,Diane Warden,George Niederehe,Michael E. Thase,Philip W. Lavori,Barry D. Lebowitz,Patrick J. McGrath,Jerrold F. Rosenbaum,Harold A. Sackeim,David J. Kupfer,James F. Luther,Maurizio Fava +15 more
TL;DR: The acute and longer-term treatment outcomes associated with each of four successive steps in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial are described and compared.
Journal ArticleDOI
A simple practice guide for dose conversion between animals and human.
Anroop B. Nair,Shery Jacob +1 more
TL;DR: This review provides basic information about translation of doses between species and estimation of starting dose for clinical trials using allometric scaling and the method of calculation of injection volume for parenteral formulation based on human equivalent dose.
Journal ArticleDOI
Antidepressant effects of ketamine in depressed patients
Robert M. Berman,Angela Cappiello,Amit Anand,Amit Anand,Dan A. Oren,Dan A. Oren,George R. Heninger,Dennis S. Charney,Dennis S. Charney,John H. Krystal,John H. Krystal +10 more
TL;DR: A first placebo-controlled, double-blinded trial to assess the treatment effects of a single dose of an N-methyl-D-aspartate (NMDA) receptor antagonist in patients with depression suggests a potential role for NMDA receptor-modulating drugs in the treatment of depression.
Journal ArticleDOI
A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Major Depression
Carlos A. Zarate,Jaskaran Singh,Paul J. Carlson,Nancy E. Brutsche,Rezvan Ameli,David A. Luckenbaugh,Dennis S. Charney,Husseini K. Manji +7 more
TL;DR: Robust and rapid antidepressant effects resulted from a single intravenous dose of an N-methyl-D-aspartate antagonist; onset occurred within 2 hours postinfusion and continued to remain significant for 1 week.